August 31, 2011 Margaret E. Valeur-Jensen, Ph.D., J.D. Dear Meg:Neurocrine Biosciences Inc • October 31st, 2011 • Biological products, (no disgnostic substances) • California
This letter sets forth the terms of the Separation and Transition Agreement (“Agreement”) that Neurocrine Biosciences, Inc. (the “Company”) is offering you in connection with your employment transition. This Agreement will become effective upon the “Effective Date” as specified in Section 17 below. As of the Effective Date, this Agreement shall supersede and replace in its entirety your Amended and Restated Employment Agreement with the Company as most recently amended on December 15, 2010 (the “Prior Employment Agreement”).
ContractCollaboration and License Agreement • October 31st, 2011 • Neurocrine Biosciences Inc • Biological products, (no disgnostic substances)
First Amendment (“First Amendment”) to the Collaboration And License Agreement dated as of June 15, 2010 (the “Collaboration Agreement”) by and between Abbott International Luxembourg S.à r.l., a corporation organized and existing under the laws of Luxembourg, with offices at 26, Boulevard Royal, L-2449 Luxembourg (“Abbott”) and Neurocrine Biosciences, Inc., a corporation organized and existing under the laws of Delaware with offices at 12780 El Camino Real, San Diego, California 92130 (“Neurocrine”) is made this thirty-first day of August, 2011 (“First Amendment Effective Date”).
